Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The progression of chronic myelogenous leukemia (CML) to blast crisis is supported by self-renewing leukemic stem cells. In normal mouse hematopoietic stem cells, the process of self-renewal involves the beta-catenin-signaling pathway. We investigated whether leukemic stem cells in CML also use the beta-catenin pathway for self-renewal. METHODS: We used fluorescence-activated cell sorting to isolate hematopoietic stem cells, common myeloid progenitors, granulocyte-macrophage progenitors, and megakaryocyte-erythroid progenitors from marrow during several phases of CML and from normal marrow. BCR-ABL, beta-catenin, and LEF-1 transcripts were compared by means of a quantitative reverse-transcriptase-polymerase-chain-reaction assay in normal and CML hematopoietic stem cells and granulocyte-macrophage progenitors. Confocal fluorescence microscopy and a lymphoid enhancer factor/T-cell factor reporter assay were used to detect nuclear beta-catenin in these cells. In vitro replating assays were used to identify self-renewing cells as candidate leukemic stem cells, and the dependence of self-renewal on beta-catenin activation was tested by lentiviral transduction of hematopoietic progenitors with axin, an inhibitor of the beta-catenin pathway. RESULTS: The granulocyte-macrophage progenitor pool from patients with CML in blast crisis and imatinib-resistant CML was expanded, expressed BCR-ABL, and had elevated levels of nuclear beta-catenin as compared with the levels in progenitors from normal marrow. Unlike normal granulocyte-macrophage progenitors, CML granulocyte-macrophage progenitors formed self-renewing, replatable myeloid colonies, and in vitro self-renewal capacity was reduced by enforced expression of axin. CONCLUSIONS: Activation of beta-catenin in CML granulocyte-macrophage progenitors appears to enhance the self-renewal activity and leukemic potential of these cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both myelodysplastic syndrome (Pang et al., 2013) and acute and chronic myelogenous leukemias begin with nonlethal mutations in the HSC pool, often leading to successful expansion of mutant HSC clones at the expense of normal HSC, and which progress eventually to leukemia (Corces-Zimmerman et al., 2014; Jamieson et al., 2004; Jan et al., 2012)”
From Quiescent Hematopoietic Stem Cells Accumulate DNA Damage during Aging that Is Repaired upon Entry into Cell Cycle (2014) · cites this paper as Jamieson et al., 2004
In the citing paper
“Although CML is considered a HSC-initiated disease, studies indicate that granulocyte-monocyte progenitors isolated from advanced-phase CML patients reacquire self-renewal properties and therefore may also serve as LSC.6”
From Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo (2010) · cites this paper as [6]
In the citing paper
“Although CML is considered a HSC-initiated disease, studies indicate that granulocyte-monocyte progenitors isolated from advanced-phase CML patients reacquire self-renewal properties and therefore may also serve as LSC.6”
From Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo (2010) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., & Kinzler, K. W. (1997) · Science · doi:10.1126/science.275.5307.1787 · Cited by 3,942
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Self-citationConstitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC −/− Colon Carcinoma
Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B., & Clevers, H. (1997) · Science · doi:10.1126/science.275.5307.1784 · Cited by 2,905
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617
Self-citationA minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
Self-citationA role for Wnt signalling in self-renewal of haematopoietic stem cells
Reya, T., Duncan, A. W., Ailles, L., Domen, J., Scherer, D. C., Willert, K., Hintz, L., Nusse, R., & Weissman, I. L. (2003) · Nature · doi:10.1038/nature01593 · Cited by 2,159
Self-citation
Cited by
Items 401–500 of 1,000
Chronic Myeloid Leukemia: Beyond BCR-ABL1
Zhou, T., Medeiros, L. J., & Hu, S. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0474-6 · Cited by 89
Nakahara, F., Sakata‐Yanagimoto, M., Komeno, Y., Kato, N., Uchida, T., Haraguchi, K., Kumano, K., Harada, Y., Harada, H., Kitaura, J., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222836 · Cited by 82
BCR/ABL, DNA damage and DNA repair: Implications for new treatment concepts
Skórski, T. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/03093640701859089 · Cited by 81
“CD34þ population, which consists of stem and early progenitor cells, express high levels of BCR/ABL [26,27].”
BackgroundEpigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation
Bhagat, T. D., Chen, S., Bartenstein, M., Barlowe, A. T., Ahrens, D. V., Choudhary, G. S., Tivnan, P., Amin, E. M., Marcondes, A. M., Sanders, M. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0282 · Cited by 82
“Our study is in line with other reports that suggest that b-catenin can cooperate with HOXA9/MEIS1 in GMPs and with BCR-ABL in CML models (41, 42).”
Issa, G. C., Kantarjian, H. M., Gonzalez, G. N., Borthakur, G., Tang, G., Wierda, W., Sasaki, K., Short, N. J., Ravandi, F., Kadia, T., et al. (2017) · Blood · doi:10.1182/blood-2017-07-792143 · Cited by 72
Stem/Progenitor Cells in Mouse Mammary Gland Development and Breast Cancer
Li, Y., & Rosen, J. M. (2005) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-005-2537-2 · Cited by 73
“This may ultimately result in recurrence or metastasis even when remarkable initial responses are observed clinically ( 12 ).”
BackgroundManagement of Chronic Myeloid Leukemia in Advanced Phase
Bonifacio, M., Stagno, F., Scaffidi, L., Krampera, M., & Raimondo, F. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01132 · Cited by 82
“Biological variables associated to a high risk of progression included CIP2A levels (165), the expression levels of the polycomb group BMI1 gene (166), the activation of betacatenin (167), specific gene signatures (168), and mutations in cancer-associated genes such as ASXL1, IKZF1, RUNX1, SETD1B, GATA2, MLL, and UBE2…”
BackgroundKo, T. K., Javed, A., Lee, K. L., Pathiraja, T. N., Liu, X., Malik, S., Soh, S. X., Heng, X. T., Takahashi, N., Tan, J. H. J., et al. (2020) · Blood · doi:10.1182/blood.2020004834 · Cited by 72
Kühnl, A., Gökbuget, N., Kaiser, M., Schlee, C., Stroux, A., Burmeister, T., Mochmann, L. H., Hoelzer, D. F., Hofmann, W., Thiel, E., et al. (2011) · Blood · doi:10.1182/blood-2011-04-350850 · Cited by 78
“Overall cohort (N 230) 47 (35-59) 27 (8-47) .”
Leukemia Stem Cells in Acute Myeloid Leukemia
Chan, W.-I., & Huntly, B. J. P. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.003 · Cited by 87
Metzeler, K. H., Heilmeier, B., Edmaier, K. E., Rawat, V. P. S., Dufour, A. M., Döhner, K., Feuring‐Buske, M., Braess, J., Spiekermann, K., Büchner, T., et al. (2012) · Blood · doi:10.1182/blood-2012-02-411827 · Cited by 76
“Median platelet count, 109/L (range) 64 (6-280) 48 (9-471) .”
Ricci-Vitiani, L., Pagliuca, A., Palio, E., Zeuner, A., & De Maria, R. (2008) · Gut · doi:10.1136/gut.2007.127837 · Cited by 72
“lack the proper stem cell self-renewal capacity, as has been proposed to occur in chronic myeloid leukaemia.(29) This possibility implies that a progenitor cell must acquire mutations associated with the reestablishment of the property to self-renew (fig 4).”
BackgroundWang, J., Xu, Y., Wan, H., & Hu, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.063 · Cited by 72
Grumolato, L., Liu, G., Haremaki, T., Mungamuri, S. K., Mong, P. Y., Akiri, G., Lopez‐Bergami, P., Arita, A., Anouar, Y., Mlodzik, M., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003603 · Cited by 82
Calabretta, B., & Salomoni, P. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.546913 · Cited by 76
Wnt/β-catenin signaling in bone marrow niche
Ahmadzadeh, A., Norozi, F., Shahrabi, S., Shahjahani, M., & Saki, N. (2015) · Cell and Tissue Research · doi:10.1007/s00441-015-2300-y · Cited by 83
Bornhäuser, M., Mohr, B., Oelschlaegel, U., Bornhauser, P., Jacki, S., Ehninger, G., & Thiede, C. (2007) · Leukemia · doi:10.1038/sj.leu.2404730 · Cited by 76
Chronic Myelogenous Leukemia, Version 1.2015
O’Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., Curtin, P. T., DeAngelo, D. J., Deininger, M. W., Devine, S. M., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0159 · Cited by 76
Cancer stem cell hypothesis in thyroid cancer
Zhang, P., Zuo, H., Ozaki, T., Nakagomi, N., & Kakudo, K. (2006) · Pathology International · doi:10.1111/j.1440-1827.2006.01995.x · Cited by 70
Agarwal, P., Zhang, B., Ho, Y., Cook, A., Li, L., Mikhail, F. M., Wang, Y., McLaughlin, M. E., & Bhatia, R. (2017) · Blood · doi:10.1182/blood-2016-05-714089 · Cited by 70
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
Arrigoni, E., Re, M. D., Galimberti, S., Restante, G., Rofi, E., Crucitta, S., Baratè, C., Petrini, M., Danesi, R., & Paolo, A. D. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0175 · Cited by 73
The INK4-ARF (CDKN2A/B) Locus in Hematopoiesis and BCR-ABL-induced Leukemias
Williams, R. T., & Sherr, C. J. (2008) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2008.73.039 · Cited by 81
Insco, M. L., Bailey, A. S., Kim, J. J., Olivares, G. H., Wapinski, O. L., Tam, C. H., & Fuller, M. T. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.08.012 · Cited by 82
“The mechanisms that limit the number of TA divisions and initiate terminal differentiation thus may provide tumor suppressor function, and defects may contribute to progression toward cancer in adult stem cell lineages (Clarke and Fuller, 2006; Jamieson et al., 2004; Krivtsov et al., 2006).”
Chronic Myeloid Leukemia Stem Cells
Jamieson, C. H. M. (2008) · Hematology · doi:10.1182/asheducation-2008.1.436 · Cited by 78
“The discovery of the Philadelphia chromosome followed by identification of its BCR-ABL fusion gene product and the resultant constitutively active P210 BCR-ABL tyrosine kinase, prompted the unraveling of the molecular pathogenesis of CML. Groundbreaking research demonstrating that BCR-ABL was necessary and sufficient…”
BackgroundInfluentialBCR-ABL in Chronic Myelogenous Leukemia – How Does It Work?
Goldman, J. M., & Melo, J. V. (2008) · Acta Haematologica · doi:10.1159/000140633 · Cited by 72
“forming a larger target for new mutations. Second, the fact that some blastic transformations are predominantly myeloid while others are lymphoid also suggests, but does not prove, that the target cell for the transforming event may already be committed to different lineages. Third, the recent demonstration that in so…”
BackgroundCommon Themes of Dedifferentiation in Somatic Cell Reprogramming and Cancer
Daley, G. Q. (2008) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2008.73.041 · Cited by 81
Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis
Døsen, G., Tenstad, E. M., Nygren, M. K., Stubberud, H., Funderud, S., & Rian, E. (2006) · BMC Immunology · doi:10.1186/1471-2172-7-13 · Cited by 72
“Both in murine HSC [34], developing thymocytes [25] and a wide range of cancer cells [31,42], elevated levels of β-catenin lead to increased cell proliferation.”
BackgroundCancer stem cells, lymphangiogenesis, and lymphatic metastasis
Li, S., & Li, Q. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.013 · Cited by 68
Managing resistance in chronic myeloid leukemia
Roychowdhury, S., & Talpaz, M. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.09.001 · Cited by 69
“Increasing genomic instability is suggested by the successively increasing frequency of KD mutations in patients with accelerated phase, myeloid blast phase, and lymphoid blast phase respectively.(20,24,22)”
BackgroundWang, L., O’Leary, H. A., Fortney, J. E., & Gibson, L. F. (2007) · Blood · doi:10.1182/blood-2007-01-068122 · Cited by 66
“This observation is consistent with a recent report that upregulation of Bcr-abl transcripts, followed by nuclear translocation of β-catenin, plays an important role during LSC transformation to CML blast crisis.(33) Co-expression of VE-cadherin and Bcr-abl are unique to the subset of putative LSCs utilized in this mo…”
ResultAshihara, E., Kawata, E., Nakagawa, Y., Shimazaski, C., Kuroda, J., Taniguchi, K., Uchiyama, H., Tanaka, R., Yokota, A., Takeuchi, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1350 · Cited by 66
Epigenetic inactivation of secreted Frizzled‐related proteins in acute myeloid leukaemia
Jost, E., Schmid, J., Wilop, S., Schubert, C., Suzuki, H., Herman, J. G., Osieka, R., & Galm, O. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07242.x · Cited by 69
“More recently, epigenetic disturbances, such as aberrant promoter hypermethylation and covalent histone modifications, have been implicated in the pathogenesis of leukaemia (Nguyen et al, 2000; Jones & Baylin, 2002; Esteller, 2003; Galm et al, 2006).”
BackgroundNormal and leukaemic stem cells
Bonnet, D. A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05596.x · Cited by 80
“It has recently been reported that, when the disease progresses to its acute blast crisis phase, a population of GMP acquires a new transformation event (activation of the b-catenin pathway), gains self-renewal capacity, and becomes leukaemogenic (Jamieson et al, 2004).”
BackgroundGiuntoli, S., Rovida, E., Barbetti, V., Cipolleschi, M. G., Olivotto, M., & Sbarba, P. D. (2006) · Leukemia · doi:10.1038/sj.leu.2404224 · Cited by 66
“Thus, the rescue of BCRsAbl expression in the course of clonal expansion most likely occurred at the CFC level, in keeping with the finding that BCRsAbl expression increases mainly in committed clonogenic progenitors during disease progression”
ResultOh, S. T., & Gotlib, J. R. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.28 · Cited by 79
Adult stem and transit-amplifying cell location.
Díaz‐Flores, L., Madrid, J. F., Gutiérrez, R., Varela, H., Valladares, F., Alvarez-Argüelles, H., & Díaz‐Flores, L. (2006) · PubMed · doi:10.14670/hh-21.995 · Cited by 85
Inflammation linking EMT and cancer stem cells
Zhou, C., Liu, J., Tang, Y., & Liang, X. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.06.005 · Cited by 71
Mustjoki, S. M., Richter, J. R., Barbany, G., Ehrencrona, H., Fioretos, T., Gedde‐Dahl, T., Gjertsen, B. T., Hovland, R., Hernesniemi, S., Josefsen, D., et al. (2013) · Leukemia · doi:10.1038/leu.2013.19 · Cited by 68
Tjwa, M., Sidenius, N., Moura, R., Jansen, S., Theunissen, K., Andolfo, A., De Mol, M., Dewerchin, M., Moons, L., Blasi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36010 · Cited by 65
Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders
Levine, R. L., & Wernig, G. (2006) · Hematology · doi:10.1182/asheducation-2006.1.233 · Cited by 77
Eradication of Leukemia Stem Cells as a New Goal of Therapy in Leukemia
Ravandi, F., & Estrov, Z. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1879 · Cited by 80
Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.
Chalandon, Y., & Schwaller, J. (2005) · PubMed · Cited by 76
Inflammation and Prostate Cancer
Tewari, A. K., Stockert, J. A., Yadav, S. S., Yadav, K. K., & Khan, I. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-95693-0_3 · Cited by 68
Wnts are dispensable for differentiation and self-renewal of adult murine hematopoietic stem cells
Kabiri, Z., Numata, A., Kawasaki, A., Edison, Tenen, D. G., & Virshup, D. M. (2015) · Blood · doi:10.1182/blood-2014-09-598540 · Cited by 68
“Abnormal b-catenin signaling has been implicated in chronic myelogenous leukemia and acute myelogenous leukemia.(51,52) Our data are not inconsistent with studies that demonstrate that stabilization of b-catenin in leukemia occurs from diverse downstream events such as inactivation of GSK3 and increased translation of…”
ResultChen, D., Wu, C., Zhao, S., Geng, Q., Gao, Y., Li, X., Zhang, Y., & Wang, Z. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004797 · Cited by 69
In vivo imaging of hematopoietic stem cells and their microenvironment
Celso, C. L., Wu, J. W., & Lin, C. P. (2009) · Journal of Biophotonics · doi:10.1002/jbio.200910072 · Cited by 76
Origin of Cancer Stem Cells: The Role of Self-Renewal and Differentiation
Wu, X.-Z. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9695-y · Cited by 77
“Activation of b-catenin in CML granulocyte-macrophage progenitors seems to enhance the self-renewal activity and leukemic potential of these cells.(31) When transduced with a leukemogenic MLL fusion gene, prospectively isolated stem cells and myeloid progenitor populations with granulocyte/macrophage differentiation p…”
BackgroundFoo, J., Drummond, M. W., Clarkson, B. D., Holyoake, T. L., & Michor, F. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000503 · Cited by 70
“, we predict that the rate of progression is lowest during treatment strategies that most effectively deplete progenitor cells if blast crisis stem cells arise from the progenitor pool”
BackgroundYang, H., Chennamaneni, L. R., Ho, M. W. T., Ang, S. H., Tan, E. S. W., Jeyaraj, D. A., Yeap, Y. S., Liu, B., Ong, E. H., Joy, J. K., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01714 · Cited by 65
Jiang, X., Forrest, D. L., Nicolini, F. E., Turhan, A. G., Guilhot, J., Yip, C. K., Holyoake, T. L., Jørgensen, H. G., Lambie, K., Saw, K. M., et al. (2010) · Blood · doi:10.1182/blood-2009-05-222471 · Cited by 66
Critical molecular pathways in cancer stem cells of chronic myeloid leukemia
Chen, Y., Peng, C., Sullivan, C., Li, D., & Li, S. (2010) · Leukemia · doi:10.1038/leu.2010.143 · Cited by 68
Leukemia stem cells in 2010: Current understanding and future directions
Becker, M. W., & Jordan, C. T. (2011) · Blood Reviews · doi:10.1016/j.blre.2010.11.001 · Cited by 72
Effect of Dedifferentiation on Time to Mutation Acquisition in Stem Cell-Driven Cancers
Jilkine, A., & Gutenkunst, R. N. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003481 · Cited by 72
“he early phases of CML, in patients with CML blast crisis, granulocyte–macrophage progenitors are thought to acquire self-renewal capacity through a β-catenin mutation and emerge as the probable CSCs [19]. Using mathematical modeling to investigate the likelihood of mutation occurring in a progenitor versus a stem cel…”
BackgroundLenaerts, T., Pacheco, J. M., Traulsen, A., & Dingli, D. (2009) · Haematologica · doi:10.3324/haematol.2009.015271 · Cited by 68
Borthakur, G. M., Kantarjian, H. M., Daley, G. Q., Talpaz, M., O'Brien, S. M., Garcia‐Manero, G., Giles, F. J., Faderl, S. H., Sugrue, M. M., & Cortes, J. E. (2005) · Cancer · doi:10.1002/cncr.21590 · Cited by 64
“In addition, it has been suggested that the CML stem cell is dormant and insensitive to the effect of imatinib, leading to persistence after therapy with imatinib.(28,29) Some studies suggest that lonafarnib might be the most effective agent in decreasing the number of such quiescent cells when combined with imatinib.”
BackgroundFrom mRNA Metabolism to Cancer Therapy: Chronic Myelogenous Leukemia Shows the Way
Perrotti, D., & Neviani, P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2320 · Cited by 63
“org Clin Cancer Res 2007;13(6) March15, 2007 1641”
InfluentialThe crossroads between cancer stem cells and aging
Franco, S. S., Raveh-Amit, H., Kobolák, J., Al-Qahtani, M. H., Mobasheri, A., & Dinnyés, A. (2015) · BMC Cancer · doi:10.1186/1471-2407-15-s1-s1 · Cited by 66
“The acquisition of self-renewal capability in progenitor cells may induce leukaemia, as observed by the expression of the MLL-ENL [75], MOZ-TIF2 [76], and MLLAF9 oncogenes, or by the activation of b-catenin [77] in progenitor cells of the hematopoietic system.”
BackgroundDPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia
Valent, P., Sadovnik, I., Ráčil, Z., Herrmann, H., Blatt, K., Cerny‐Reiterer, S., Eisenwort, G., Lion, T., Holyoake, T. L., & Mayer, J. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12368 · Cited by 65
Lin, L.-C., Yeh, C., Kuo, C., Lee, C., Yen, G., Wang, L.-S., Wu, C., Yang, W. V., & Wu, A. T. H. (2012) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf301981n · Cited by 66
Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis
Thomas, E. K., Cancelas, J. A., Zheng, Y., & Williams, D. A. (2008) · Leukemia · doi:10.1038/leu.2008.71 · Cited by 60
Stem Cells and Cancer: An Overview
Sales, K. M., Winslet, M. C., & Seifalian, A. M. (2007) · Stem Cell Reviews and Reports · doi:10.1007/s12015-007-9002-0 · Cited by 69
“have suggested that cancer stem cells can be derived from stem cells, as well as the committed short-lived progenitors, giving rise to tumours with comparable latencies, phenotypes and gene expression profiles [17–19].”
BackgroundWelte, K., & Zeidler, C. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.01.013 · Cited by 68
An RNA editing fingerprint of cancer stem cell reprogramming
Crews, L. A., Jiang, Q., Zipeto, M., Lazzari, E., Court, A. C., Ali, S. A., Barrett, C. L., Frazer, K. A., & Jamieson, C. H. M. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-014-0370-3 · Cited by 67
“For primary patient-derived LSC purification, CD34selected cells were stained with fluorescent antibodies against human CD34, CD38, lineage markers (cocktail, all antibodies from BD Biosciences, San Diego, CA) and propidium iodide as previously described [1,23,24].”
MethodCurrent Status and Issues in Cancer Stem Cell Study
Yang, Y., & Chang, J. (2008) · Cancer Investigation · doi:10.1080/07357900801901856 · Cited by 69
“For example, a mutation that enhances nuclear h-catenin in granulocyte-macrophage progenitor cells causes a blast crisis in some patients with chronic myeloid leukemia (43) when the mutated progenitor cells acquire the capacity for selfrenewal and undergo unlimited growth as cancer cells (44, 45).”
BackgroundSelective elimination of leukemia stem cells: Hitting a moving target
Crews, L. A., & Jamieson, C. H. M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.006 · Cited by 67
“to be increased in the blast crisis stage of disease [13].”
BackgroundInfluentialKvinlaug, B. T., & Huntly, B. J. P. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.7.915 · Cited by 72
“Pathways such as the HOX gene [55,56] , WNT/ β -catenin [57,58] , Notch [59] , phosphatase and tension homologue (PTEN) [60,61] , Hedgehog [62] and BMI-1 [63,64] have all been found to be altered in human cancers and are all implicated in the maintenance of normal stem cells [60,61,64-69] .”
BackgroundBaba, Y., Yokota, T., Spits, H., Garrett, K. P., Hayashi, S.-I., & Kincade, P. W. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2294 · Cited by 74
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check
O’Hare, T., Eide, C. A., & Deininger, M. W. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.865 · Cited by 69
“Recent evidence suggests that more committed progenitor cells may acquire self-renewal properties, and that acquisition of this capability may be a key to the transition to blast crisis [99,100] .”
BackgroundMechanisms of resistance to BCR-ABL and other kinase inhibitors
Lamontanara, A. J., Akçok, E. B. G., Kuzyk, O., & Hantschel, O. D. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.12.009 · Cited by 71
“BCR-ABL was also higher expressed in granulocyte macrophage progenitors in blast crisis CML cells when compared to chronic phase cells [50].”
BackgroundMorgan, G., Pearn, L., Liddiard, K., Pumford, S. L., Burnett, A. K., Tonks, A., & Darley, R. L. (2012) · Leukemia · doi:10.1038/leu.2012.221 · Cited by 60
The mammary cellular hierarchy and breast cancer
Oakes, S. R., Gallego‐Ortega, D., & Ormandy, C. J. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1674-4 · Cited by 73
“Research in hematopoietic malignancies provides evidence that committed progenitors cells may serve as cells of origin for malignancy [129].”
Yong, A. S. M., Keyvanfar, K., Hensel, N. F., Eniafe, R. B., Savani, B. N., Berg, M., Lundqvist, A., Adams, S. D., Sloand, E. M., Goldman, J. M., et al. (2008) · Blood · doi:10.1182/blood-2008-05-158253 · Cited by 62
Sims‐Mourtada, J., Opdenaker, L. M., Davis, J. J., Arnold, K. M., & Flynn, D. C. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22225 · Cited by 67
Sundaram, D. N. M., Jiang, X., Brandwein, J. M., Valencia‐Serna, J., Remant, K. C. B., & Uludağ, H. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.007 · Cited by 66
Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
Valent, P., Sadovnik, I., Eisenwort, G., Bauer, K., Herrmann, H., Gleixner, K. V., Schulenburg, A., Rabitsch, W., Sperr, W. R., & Wolf, D. G. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174233 · Cited by 66
“Similarly, in the blast phase of Ph+ CML, LSC appear to express CD38 [31], and the same holds true for Ph+ and Ph− acute lymphoblastic leukemia (ALL) [32].”
BackgroundMacLean, A. L., Filippi, S., & Stumpf, M. P. H. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317072111 · Cited by 58
Eaf1 and Eaf2 negatively regulate canonical Wnt/β-catenin signaling
Liu, J., Zhang, D., Xie, X., Ouyang, G., Liu, X., Sun, Y., & Xiao, W. (2013) · Development · doi:10.1242/dev.086157 · Cited by 64
“Indeed, multiple cancers, such as colon cancer, hair follicle tumors, prostate cancer and leukemia, show a high frequency of aberrant stabilization and constitutive activation of β-catenin (Morin et al., 1997; Chan et al., 1999; Jamieson et al., 2004; Lo Celso et al., 2004).”
BackgroundZaro, B. W., Noh, J. J., Mascetti, V. L., Demeter, J., George, B., Zukowska, M., Gulati, G. S., Sinha, R., Flynn, R. A., Banuelos, A., et al. (2020) · eLife · doi:10.7554/elife.62210 · Cited by 58
“DOI: https://doi.org/10.7554/eLife.62210 1 of 29 normal HSCs (Tomasetti et al., 2017; Jan et al., 2012; Miyamoto et al., 2000; Jamieson et al., 2004; Rossi et al., 2008; Pang et al., 2013; Busque et al., 2018).”
InfluentialNaka, K., Hoshii, T., & Hirao, A. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01584.x · Cited by 63
Testa, U. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1118-7 · Cited by 71
“, CD34CD38, expressed high levels of BCR-ABL and had an activated Wnt/beta-catenin self-renewal pathway [132].”
The Implications of Cancer Stem Cells for Cancer Therapy
Jiang, W., Peng, J., Zhang, Y., Cho, W., & Jin, K. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131216636 · Cited by 70
“This could be found in chronic myelogenous leukemia, which showed that a lineage-restricted progenitor or mature cell can acquire stem cell privileges after oncogenic transformation [53–55].”
BackgroundKim, Y., Ma, H., Oehler, V. G., Gang, E. J., Nguyen, C., Masiello, D., Liu, H., Zhao, Y., Radich, J. P., & Kahn, M. R. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794328420 · Cited by 60
“In CML, -catenin-dependent signaling has been shown to play a role in the expansion of granulocytemacrophage progenitors and appears to promote self-renewal activity and increased leukemic potential in advanced phase disease [48].”
BackgroundChronic myeloid leukaemia: stem cell derived but progenitor cell driven
Marley, S. B., & Gordon, M. Y. (2005) · Clinical Science · doi:10.1042/cs20040336 · Cited by 61
Wnt Pathway: An Integral Hub for Developmental and Oncogenic Signaling Networks
Sharma, M., & Pruitt, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218018 · Cited by 63
“Moreover, different subsets of AML, ALL, and BCR-ABL chronic myeloid leukemia (CML) cells rely on both β-catenin-mediated signaling and Wnt-mediated calcium signaling for self-renewal, proliferation, and survival [98,99].”
BackgroundThe variety of leukemic stem cells in myeloid malignancy
Wiseman, D. H., Greystoke, B., & Somervaille, T. C. P. (2013) · Oncogene · doi:10.1038/onc.2013.269 · Cited by 63
Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics
Tabatabai, R., Linhares, Y. P. L., Bolos, D., Mita, M. M., & Mita, A. C. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0507-4 · Cited by 61
“CML GM progenitors were found to have elevated levels of nuclear β-catenin in comparison to normal GM progenitors, while their self-renewing capacity is reduced by axin expression [127].”
BackgroundCharacterization of LEF1 High Expression and Novel Mutations in Adult Acute Lymphoblastic Leukemia
Guo, X. L., Zhang, R., Liu, J., Li, M., Song, C., Dovat, S., Li, J., & Ge, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125429 · Cited by 61
“Aberrant expression of LEF1 has been reported to be involved in solid cancers and leukemia [4,10–12]; and LEF1 is required for the growth of leukemia cells [13,14].”
BackgroundTreatment of blast phase chronic myeloid leukaemia: A rare and challenging entity
Copland, M. (2022) · British Journal of Haematology · doi:10.1111/bjh.18370 · Cited by 66
Dzobo, K., Senthebane, D. A., Rowe, A., Thomford, N. E., Mwapagha, L. M., Al-Awwad, N., Dandara, C., & Parker, M. I. (2016) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2016.0152 · Cited by 59
“Many signaling pathways appear to be common in both CSCs and normal stem cells (Dzobo et al., 2015; Hsu et al., 2016; Jamieson et al., 2004; Krivtsov et al., 2006; Leon et al., 2016; Pece et al., 2010; Shen et al., 2016; Wang et al., 2010).”
Wnt Signaling in Hematological Malignancies
Grainger, S. J., Traver, D. J., & Willert, K. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.002 · Cited by 58
Regulation of self‐renewal in normal and cancer stem cells
Falzacappa, M. V. V., Ronchini, C., Reavie, L. B., & Pelicci, P. G. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08727.x · Cited by 72
Cancer stem cells: A stride towards cancer cure?
Sengupta, A., & Cancelas, J. A. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22213 · Cited by 56
“Second, a lineage committed progenitor cell can also function like a CSC by acquiring self-renewal properties, and behave as a cell of origin of disease transformation (Jamieson et al., 2004).”
BackgroundPark, C. Y., Majeti, R., & Weissman, I. L. (2008) · Nature Protocols · doi:10.1038/nprot.2008.194 · Cited by 56
“In addition to engrafting human HSC, these mice are also permissive for growing numerous human tumor types, including hematopoietic and solid tumor”
BackgroundChronic myeloid leukemia: a model for oncology
Hehlmann, R., Berger, U., & Hochhaus, A. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1039-z · Cited by 66
TARGET: a survey of real‐world management of chronic myeloid leukaemia across 33 countries
Turkina, A., Wang, J., Mathews, V., Saydam, G., Jung, C. W., Hashmi, H. H. A., Yassin, M. A., Clanche, S. L., Miljkovic, D., Slader, C., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16599 · Cited by 56
Multiple Signaling Pathways Converge on β-Catenin in Thyroid Cancer
Abbosh, P. H., & Nephew, K. P. (2005) · Thyroid · doi:10.1089/thy.2005.15.551 · Cited by 56
Heterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation
Gandillet, A., Park, S., Lassailly, F., Griessinger, E., Vargaftig, J., Filby, A. J., Lister, T. A., & Bonnet, D. A. (2011) · Leukemia · doi:10.1038/leu.2011.17 · Cited by 58
Treatment of chronic myeloid leukemia in blast crisis
Hehlmann, R., & Saußele, S. (2008) · Haematologica · doi:10.3324/haematol.2008.001214 · Cited by 55
“progenitors which appears to enhance self-renewal activity and leukemic potential.(32)”
BackgroundStrategies to eliminate cancer stem cells: Clinical implications
Huff, C. A., Matsui, W. H., Smith, B. D., & Jones, R. J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.045 · Cited by 58
p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells
Peterson, L. F., Mitrikeska, E., Giannola, D. M., Lui, Y., Sun, H., Bixby, D. L., Malek, S. N., Donato, N. J., Wang, S., & Talpaz, M. (2011) · Leukemia · doi:10.1038/leu.2011.7 · Cited by 62
Metadata
- Authors
- Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., Sawyers, C. L., & Weissman, I. L.
- Affiliations
- Stanford Medicine (US)
- University of Toronto (CA)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-08-12
- Volume
- 351
- Issue
- 7
- Pages
- 657-667
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2012962381
- Cited by
- 1,485
- References
- 58
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 19 · 2023: 36 · 2022: 27 · 2021: 33 · 2020: 40 · 2019: 37 · 2018: 40 · 2017: 53 · 2016: 80 · 2015: 74 · 2014: 81 · 2013: 95 · 2012: 114
- FWCI
- 55.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (K23HL04409, K23HL004409)
- National Cancer Institute (2PO1CA49605, CA 86017, CA 55209, R01CA086017, P01CA049605)
- National Institute of Allergy and Infectious Diseases (5 T32 AI07290, T32AI007290)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- chronic myeloid leukemia, blast crisis, leukemia stem cells, CFU-GM, β-catenin signaling, BCR-ABL, self-renewal, Axin, imatinib resistance, hematopoietic stem cells, myeloid progenitor cells
- MeSH terms
- Imatinib Mesylate, Adult, Aged, Antineoplastic Agents, Benzamides, Blast Crisis, Colony-Forming Units Assay, Cytoskeletal Proteins, DNA-Binding Proteins, Female, Granulocytes, Hematopoietic Stem Cells, Humans, Macrophages, Male, Middle Aged, Piperazines, Pyrimidines, RNA, Neoplasm, Transcription Factors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Trans-Activators, Fusion Proteins, bcr-abl, Microscopy, Confocal, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, beta Catenin, Lymphoid Enhancer-Binding Factor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.